August 17, 2020 -- HiFiBio Therapeutics and the Coronavirus Immunotherapy Consortium (CoVIC) will collaborate to develop SARS-CoV-2-neutralizing antibodies with potential therapeutic and prophylactic applications.
HiFiBio has submitted 10 distinct mono- and bispecific antibodies to CoVIC for in vitro and in vivo testing. The company will get a first look into the performance of its antibodies compared to other submitted antibodies and will explore synergies among them for potential combinational therapies. Together, the collaboration seeks to accelerate development pipelines to protect vulnerable individuals from COVID-19 and bring successful immunotherapies to COVID-19 patients.
The antibodies were developed by leveraging HiFiBio's proteomics and proprietary single-cell profiling technologies. The company's Drug Intelligent Science technology allows antibody therapies to be matched with biomarkers to predict patient response.
The company is also preparing an investigational new drug application with the U.S. Food and Drug Administration for HFB30132A, a SARS-CoV-2-neutralizing antibody for the treatment of COVID-19 patients. The antibody has been evaluated in preclinical studies and a phase I clinical study is planned for later this summer.